News

A team of researchers from Johns Hopkins Medicine and the University of Wisconsin-Madison conducted a study on the application of autonomous artificial intelligence and testing for diabetic eye disease.

The future of the tech-forward surgical suite

The American Academy of Ophthalmology indicates that consumers who may see the eye color-changing drops advertised and used on TikTok or elsewhere online should be advised that they are not FDA approved.

The day will be held on October 10. It is coordinated by the International Agency for the Prevention of Blindness under the “Love Your Eyes” campaign banner, and is putting children at the center of the campaign.

A meta-analysis indicates a "significant association" between vitamin D deficiency and increased risk of RVO

Australian researchers have found that clinical registries may be an untapped font of information for artificial intelligence.

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss evidence-based evaluation for optic neuritis from big data analysis

The IOL, designed with artificial intelligence, will launch at this year's ESCRS Congress in Barcelona, Spain

The product candidate is a modifier gene therapy for broad retinitis pigmentosa indication.

The drop improves vision by breaking up degraded protein complexes that cause lens clouding

According to researchers at Nanyang Technology University Singapore, smart contact lenses can be used to correct vision, monitor the health of the user, and flag and treat diseases for patients diagnosed with chronic health conditions such as glaucoma and diabetes.

In this study, the investigators retrospectively analyzed the incidence of metastasis in 8,034 patients with uveal melanoma over a 35-year period based on tumor size category.

In a 10-year retrospective study, a team of researchers in China found the top 2 categories for cancellations were medical factors and patient-related factors.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

Hannah Chiu, MD, FRCSC, highlights some of the early benefits of an AI-operated telephone call system for postoperative patient care.

These 4 women will feature in talks across the WIO Summer Symposium. Together they welcome all attendees to the 2024 meeting in Carlsbad, California.

CN6 palsy from the COVID-19 virus is rare, and can occur in infants as young as 7 months.

The Phase 1 trial is a multicenter, open-label, dose-escalation safety clinical trial, with 18 subjects, who each have received a single periocular injection of AIV007

The option is a definitive step forward in the field of vitreoretinal surgery

Nicole Bajic, MD, shared a bit about the skills labs at the Women in Ophthalmology Summer Symposium, the value that this meeting provides, and what she is looking forward to at this event.

Christina Y. Weng, MD, MBA discussed what attendees, both virtually and in-person, can expect from this year's Women in Ophthalmology Summer Symposium meeting in Carlsbad, California. The meeting will take place August 22-25, 2024.

The next step for the research likely will focus on determining whether blocking GSK3 can reverse existing AMD damage, potentially leading to new treatment options.

The WIO Summer Symposium offers attendees a chance to network, build practice management skills, and plan to reach new goals and milestones in their career.

Rationale for delving into this topic is the recent studies that have reported that active and healthy living can reduce IOP.

At the World Ophthalmology Congress in Vancouver, Canada, John D. Sheppard, MD, MMSc, FACS, presented data on perfluorohexyloctane ophthalmic solution in the treatment of dry eye. He sat down with Ophthalmology Times to discuss the topic in further detail.

European patients navigate new therapies and market change-ups

According to a study by a team of Korean researchers, published in BMC Ophthalmology, investigators conducted a retrospective study to examine the prevalence and clinical characteristics of ocular allergy in glaucoma patients using brinzolamide 1.0%/brimonidine 0.2% fixed combination (BBFC), with and without concurrent β-blocker.